Kirnahar, India

Ashutosh Pal

This inventor holds 1 USPTO granted patent. Top assignee: The University of Texas System. Active years: 2019.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ashutosh Pal: Innovator in Anti-Cancer and Anti-Inflammatory Compounds

Introduction

Ashutosh Pal is a notable inventor based in Kirnahar, India. He has made significant contributions to the field of medicinal chemistry, particularly in developing compounds that exhibit anti-cancer and anti-inflammatory properties. His work is crucial in addressing inflammatory diseases and hyperproliferative conditions, such as cancer.

Latest Patents

Ashutosh Pal holds a patent for "Compounds for treating inflammatory and hyperproliferative diseases." This patent describes compounds that can potentially treat inflammatory diseases and hyperproliferative diseases, including cancer. The innovative compounds he has developed are designed to exhibit anti-cancer and/or anti-inflammatory properties, showcasing his commitment to advancing medical science.

Career Highlights

Pal is affiliated with The University of Texas System, where he continues to engage in research and development. His work at this prestigious institution allows him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Richard J Ford, Jr. and William G Bornmann. Their collaboration enhances the research environment and fosters innovation in the field of medicinal chemistry.

Conclusion

Ashutosh Pal's contributions to the development of anti-cancer and anti-inflammatory compounds highlight his role as an important inventor in the medical field. His work not only advances scientific knowledge but also has the potential to improve patient outcomes in treating serious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…